Acorda, Amgen and Regeneron Lead Premarket Biotech Movers


Biotech Acorda Therapeutics was soaring ahead of the market open on Thursday, thanks to positive results from a late-stage clinical trial for its inhaled formulation of levodopa, which is used to improve motor function in patients with Parkinson's disease. The company's shares were up 10% in premarket trading, hitting $22.45 apiece on the news.



from Biotech News